ATOSSA THERAPEUTICS, INC.(ATOS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ATOS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ATOSSA THERAPEUTICS, INC. (ATOS), a Healthcare sector company. ATOS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), ATOSSA THERAPEUTICS, INC. reports net income of $-9.6M, free cash flow of $-9.6M. Top institutional holders of ATOS by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, AMERIPRISE FINANCIAL, BlackRock,, based on the most recent SEC filings. ATOS trades on the Nasdaq exchange and files with the SEC under CIK 1488039. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ATOSSA THERAPEUTICS, INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-9.6M
Free Cash Flow
Q1 2026
$-9.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-68.7% YoYOperating Income
-81.0% YoYEPS (Diluted)
Total Assets
-66.3% YoYOp. Cash Flow
-80.7% YoY| Metric | FY 2025 | FY 2021 | FY 2019 | FY 2018 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1.8K |
| Net Income | $-34.8M -68.7% | $-20.6M -19.5% | $-17.2M -51.2% | $-11.4M -79.1% | $-6.4M +59.6% | $-15.8M |
| Operating Income | $-37.1M -81.0% | $-20.5M -18.9% | $-17.3M -51.0% | $-11.4M -43.5% | $-8.0M +37.5% | $-12.8M |
| EPS (Diluted) | $-4.04 | — | — | — | — | — |
| Total Assets | $47.6M -66.3% | $141.3M +874.9% | $14.5M +23.6% | $11.7M +182.8% | $4.1M -33.6% | $6.2M |
| Operating Cash Flow | $-29.8M -80.7% | $-16.5M -80.4% | $-9.1M -1.9% | $-9.0M -66.7% | $-5.4M +61.5% | $-14.0M |
AI Insight: ATOS Ratio Trends
Capital destruction accelerates sharply: ROE collapsed from -30.2% in Q2 2024 to -125.8% in Q1 2026, signaling rapidly mounting cash burn with no revenue base.
• ROE deteriorated continuously from -30.2% in Q2 2024 to -125.8% in Q1 2026, an uninterrupted eight-quarter decline.
• ROIC worsened from -35.5% in Q2 2024 to -74.3% in Q3 2025, the last quarter with available data.
• ROA deteriorated from -28.2% in Q2 2024 to -91.9% in Q4 2025, reflecting accelerating asset erosion relative to losses.
⚠ TTM ROE of -123.5% and ROA of -99.2% confirm the burn rate is consuming nearly the entire asset and equity base.
⚠ OpMargin, NPM, and D/E are entirely absent across all periods — insufficient data to assess cost structure or leverage.
Get alerted when ATOS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ATOSSA THERAPEUTICS, INC. including:
Top Institutional Holders of ATOS
VANGUARD CAPITAL MANAGEMENT LLC
$1.8M349,096 shAMERIPRISE FINANCIAL INC
$1.3M255,134 shBlackRock, Inc.
$700.5K133,169 shRENAISSANCE TECHNOLOGIES LLC
$573.4K109,007 shGEODE CAPITAL MANAGEMENT, LLC
$510.7K97,061 shUBS Group AG
$484.1K92,034 shMILLENNIUM MANAGEMENT LLC
$351.0K66,739 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$289.3K55,000 shVANGUARD FIDUCIARY TRUST CO
$274.8K52,235 shSTATE STREET CORP
$209.1K39,761 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.8M | 349,096 |
| AMERIPRISE FINANCIAL INC | $1.3M | 255,134 |
| BlackRock, Inc. | $700.5K | 133,169 |
| RENAISSANCE TECHNOLOGIES LLC | $573.4K | 109,007 |
| GEODE CAPITAL MANAGEMENT, LLC | $510.7K | 97,061 |
| UBS Group AG | $484.1K | 92,034 |
| MILLENNIUM MANAGEMENT LLC | $351.0K | 66,739 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $289.3K | 55,000 |
| VANGUARD FIDUCIARY TRUST CO | $274.8K | 52,235 |
| STATE STREET CORP | $209.1K | 39,761 |
More Healthcare Companies
View all Healthcare →Put ATOS on your watchlist
Track score changes the day ATOSSA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ATOS a good stock to buy?
13F Pro's AI-powered analysis of ATOSSA THERAPEUTICS, INC. (ATOS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATOS are available on the ATOS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ATOS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATOS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ATOSSA THERAPEUTICS, INC.'s investment landscape.